ISGLT2 in Patients Without DM With Acute MI

Inclusion Criteria : * Participant must approved the informed consent. * Confirmed MI, either STEMI or NSTEMI, according to the fourth universal definition of MI (Thygesen et al 2019). * Evidence of impaired regional or global LV systolic function at any timepoint during current MI-related hospitalisation with Ejection Fraction\<50%(established with echocardiogram, radionuclide ventriculogram, contrast angiography or cardiac MRI) or Symptoms of Acute heart failure without cardiogenic Shock. * Hemodynamically stable (no episodes of symptomatic hypotension, or arrhythmia with haemodynamic compromise in the last 24 hours). Exclusion Criteria: * Known type 1 diabetes mellitus (T1DM) or T2DM at the time for admission. * Chronic symptomatic HF with a prior HHF within the last year and known reduced ejection fraction (LVEF≤40 %), documented before the current MI hospitalization. * Patients with cardiogenic shock who received vasoactive drugs during index. * Hospitalization Severe (eGFR \<20 mL/min/1.73 m2 by local laboratory), unstable or rapidly progressing renal disease at the time of randomization * Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into the trial. * Active malignancy requiring treatment at the time of screening. * Any non-CV condition, eg malignancy, with a life expectancy of less than one years based on the investigator´s clinical judgement. * Currently on treatment, or with an indication for treatment, with a sodium glucose co-transporter 2 inhibitor (SGLT2-inhibitor)